Minimum age of 11 set for UK puberty blocker trial

Minimum Age of 11 Set for UK Puberty Blocker Trial

Minimum age of 11 set for UK - The UK has established a minimum age of 11 for children participating in a trial evaluating the risks and benefits of puberty-blocking medications. This decision follows a pause in February 2026, prompted by safety concerns raised by the Medicines and Healthcare products Regulatory Agency (MHRA), which initially proposed a higher threshold of 14. The agency suggested updating the trial’s guidelines to incorporate additional safeguards, including age restrictions, which were not previously defined.

Researchers from King’s College London have agreed to delay recruitment until after 1 August, allowing legal proceedings to conclude. The trial, approved by UK regulators and ethics panels in November 2025, will focus on children under 16 who are experiencing gender-related distress and seeking care through gender services. It aims to assess the impact of puberty-suppressing drugs on physical, social, and emotional health.

Participants must provide parental consent and demonstrate an understanding of the treatment’s effects. For female-registered individuals, the minimum age is 11, while male-registered participants must be at least 12. The trial also includes clearer guidance on stopping medication, such as if there are concerns about bone density, brain function, or vaginal bleeding. Additional details will be shared on preserving fertility.

Legal and Ethical Challenges

Some clinicians and advocacy groups have contested the trial’s safety and ethical framework. They argue that children may not fully comprehend the long-term implications of the drugs, particularly their effect on future fertility. A 2024 review by Dr. Hilary Cass highlighted gaps in evidence for gender medicine, leading to a ban on puberty blockers for those under 18. This decision followed the review’s warnings about potential risks.

"It is vital that the trial for puberty blockers in under-16s proceeds, or we'll have ongoing charlatans distributing unsuitable drugs," Cass told the BBC. She emphasized the private sale of these medications, especially online, as a concern.